Epigenetic modulators from "The Big Blue": A treasure to fight against cancer

Michael Schnekenburger, Mario Dicato, Marc Diederich*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

41 Citations (Scopus)

Abstract

Cancer remains a major public health problem in our society. The development of potent novel anti-cancer drugs selective for tumor cells is therefore still required. Deregulation of the epigenetic machinery including DNA methylation, histone modifications and non-coding RNAs is a hallmark of cancer, which provides potential new therapeutic targets. Natural products or their derivatives represent a major class of anti-cancer drugs in the arsenal available to the clinician. However, regarding epigenetically active anti-cancer agents for clinics, the oceans represent a largely untapped resource. This review focuses on marine natural compounds with epigenetic activities and their synthetic derivatives displaying anti-cancer properties including largazole, psammaplins, trichostatins and azumamides.

Original languageEnglish
Pages (from-to)182-197
Number of pages16
JournalCancer Letters
Volume351
Issue number2
DOIs
Publication statusPublished - 1 Sept 2014
Externally publishedYes

Keywords

  • Anti-cancer drugs
  • DNA methylation
  • Epigenetic
  • Histone modifications
  • Micro-RNAs
  • Natural marine compounds

Fingerprint

Dive into the research topics of 'Epigenetic modulators from "The Big Blue": A treasure to fight against cancer'. Together they form a unique fingerprint.

Cite this